Indore Online Journal

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Acute on Chronic Liver Failure (ACLF) Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of ACLF, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Acute on Chronic Liver Failure (ACLF) Market

• The market size for Acute on Chronic Liver Failure (ACLF) in the leading markets is expected to grow significantly by 2036.

• The United States accounted for the highest ACLF treatment market size in 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.

• As per DelveInsight’s analysis, the market size of ACLF in the 7MM was approximately USD 3,726 million in 2022, which is expected to increase by 2036.

• According to a meta-analysis by Allhoff et al. (2025), ACLF Grade 1 was the most frequently observed subtype globally, accounting for approximately 44% of cases, followed by Grade 2 (32%) and Grade 3 (21%).

• As per Masnou et al. (2021), the prevalence of EASL-ACLF and NACSELD-ACLF in hospitalized patients with cirrhosis were 25.3% and 7.5%, respectively.

• In patients with APASL-ACLF from five cohorts, including the AARC cohort, the most common etiologies were HBV (55%) and alcohol (29.3%).

• According to a study conducted by Hernaez et al. (2019), in the US, among the patients hospitalized for decompensated cirrhosis, 26.4% were diagnosed with ACLF upon admission.

• Leading ACLF companies such as Yaqrit Discovery, GENFIT, Seal Rock Therapeutics, Celloram, CRISPR Medicine Media, Evive Biotech, Miromatrix Medical, and others are developing new ACLF treatment therapies that can be available in the ACLF market in the coming years.

• The promising ACLF therapies in clinical trials include YAQ005, SRT-015, G1090N (nitazoxanide) capsules, CLM-022, bbHEP01, F-652, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market

Key Factors Driving the Acute on Chronic Liver Failure (ACLF) Market

• Rising Prevalence of Chronic Liver Diseases: Increasing incidence of alcohol-related liver disease, viral hepatitis, and drug-induced liver injury is contributing significantly to the growing burden of ACLF globally.

• Growing Need for Effective Disease-Modifying Therapies: Currently, there are no approved disease-modifying therapies for ACLF, creating substantial unmet medical need and demand for novel targeted treatment approaches.

• Increasing Adoption of Supportive and Intensive Care Approaches: Growing use of antiviral therapies, broad-spectrum antibiotics, liver support systems, and liver transplantation strategies is improving disease management and survival outcomes.

• Advancements in Prognostic Models and Diagnostics: Prognostic models such as CLIF-C ACLF, AARC score, and NACSELD are increasingly being utilized for mortality prediction, transplant decisions, and personalized patient management.

Acute on Chronic Liver Failure (ACLF) Competitive Landscape

• Several ACLF drugs in development include YAQ005, SRT-015, G1090N (nitazoxanide), CLM-022, bbHEP01, and F-652.

• These candidates target diverse mechanisms such as TLR4 inflammatory pathway modulation, ASK1 inhibition, inflammasome disruption, regenerative hepatocyte therapies, and anti-inflammatory approaches, aiming to improve survival outcomes and reduce multiorgan complications associated with ACLF.

Discover more about therapies set to grab major ACLF market share @ ACLF Treatment Landscape

Recent Developments in the Acute on Chronic Liver Failure (ACLF) Market

• As of December 2025, the APACHE trial evaluating short-term survival in patients with ACLF treated with Plasma Exchange With Human Serum Albumin 5%, sponsored by Grifols Therapeutics, was terminated for corporate business reasons unrelated to safety.

• In September 2025, GENFIT discontinued the development of VS-01 in ACLF after a patient suffered a serious adverse event in a Phase II trial.

• In May 2025, GENFIT unveiled promising preclinical data on CLM-022 at the European Association for the Study of the Liver (EASL) International Liver Congress 2025.

• In May 2023, Seal Rock Therapeutics entered into an out-licensing agreement with GENFIT for the development of an injectable formulation of SRT-015 for acute liver disease, including ACLF.

What is Acute on Chronic Liver Failure (ACLF)?

Acute on Chronic Liver Failure (ACLF) is a severe clinical syndrome characterized by acute deterioration of liver function in patients with pre-existing chronic liver disease, resulting in systemic inflammation, multiorgan failure, and high short-term mortality. ACLF is commonly triggered by infections, alcohol abuse, viral hepatitis, medications, or major surgery. The condition progresses rapidly and often requires intensive supportive care and consideration for liver transplantation.

Acute on Chronic Liver Failure (ACLF) Epidemiology Segmentation

The ACLF epidemiology section provides insights into the historical and current ACLF patient pool and forecasted trends for the leading markets. The ACLF market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Prevalent Cases of ACLF

• Total Diagnosed Prevalent Cases of ACLF

• Grade-specific Diagnosed Prevalent Cases of ACLF

• Gender-specific Diagnosed Prevalent Cases of ACLF

• Total Treated Cases of ACLF

Scope of the Acute on Chronic Liver Failure (ACLF) Market Report

• Therapeutic Assessment: ACLF current and emerging therapies

• ACLF Market Dynamics: Key Market Forecast Assumptions of Emerging ACLF Drugs and Market Outlook

• Key Companies: Yaqrit Discovery, GENFIT, Seal Rock Therapeutics, Celloram, CRISPR Medicine Media, Evive Biotech, Miromatrix Medical, and others

• Key Therapies: YAQ005, SRT-015, G1090N (nitazoxanide), CLM-022, bbHEP01, F-652, and others

• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

• Unmet Needs, KOL’s views, Analyst’s views, ACLF Market Access and Reimbursement

To know more about ACLF companies working in the treatment market, visit @ ACLF Clinical Trials and Therapeutic Assessment

Table of Contents

1. Acute on Chronic Liver Failure (ACLF) Market Report Introduction

2. Executive Summary for ACLF

3. SWOT Analysis of ACLF

4. ACLF Patient Share (%) Overview at a Glance

5. ACLF Market Overview at a Glance

6. ACLF Background and Overview

7. ACLF Epidemiology and Patient Population

8. Country-Specific Patient Population of ACLF

9. ACLF Current Treatment and Medical Practices

10. ACLF Unmet Needs

11. ACLF Emerging Therapies

12. ACLF Market Outlook

13. Country-Wise ACLF Market Analysis (2022–2036)

14. ACLF Market Access and Reimbursement of Therapies

15. ACLF Market Drivers

16. ACLF Market Barriers

17. ACLF Appendix

18. ACLF Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services